Literature DB >> 21178990

Application of the BRAT framework to case studies: observations and insights.

B S Levitan1, E B Andrews, A Gilsenan, J Ferguson, R A Noel, P M Coplan, F Mussen.   

Abstract

The BRAT Framework is a set of flexible processes and tools that provides a structured approach to pharmaceutical benefit-risk decision making in drug development and post approval settings. A work in progress, it consists of six steps that produce representations of key tradeoffs, with appropriate documentation of the rationale for decisions and the assumptions made in their development. This article describes insights, gained from case studies, into the Framework's performance in a variety of constructed benefit-risk scenarios, focusing on a hypothetical example of a triptan for migraine. The scenarios described illustrate the challenges inherent in arriving at many of the regulatory decisions, including obtaining data for matching populations for all outcomes, finding data of consistent quality, addressing correlated outcomes (e.g., elevated liver function tests and hepatitis rates), dealing with rare but serious adverse events (AEs), and understanding and making decisions based on information for many outcomes simultaneously. The Framework provides a structure for organizing, interpreting, and communicating relevant information, including heterogeneity in results and the quality and level of uncertainty of data, in order to facilitate benefit-risk decisions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178990     DOI: 10.1038/clpt.2010.280

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Good decision making requires good communication.

Authors:  Baruch Fischhoff
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

2.  A comparison of analytic hierarchy process and conjoint analysis methods in assessing treatment alternatives for stroke rehabilitation.

Authors:  Maarten J Ijzerman; Janine A van Til; John F P Bridges
Journal:  Patient       Date:  2012       Impact factor: 3.883

Review 3.  Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations.

Authors:  Bethea A Kleykamp; Robert H Dworkin; Dennis C Turk; Zubin Bhagwagar; Penney Cowan; Christopher Eccleston; Susan S Ellenberg; Scott R Evans; John T Farrar; Roy L Freeman; Louis P Garrison; Jennifer S Gewandter; Veeraindar Goli; Smriti Iyengar; Alejandro R Jadad; Mark P Jensen; Roderick Junor; Nathaniel P Katz; J Patrick Kesslak; Ernest A Kopecky; Dmitri Lissin; John D Markman; Michael P McDermott; Philip J Mease; Alec B O'Connor; Kushang V Patel; Srinivasa N Raja; Michael C Rowbotham; Cristina Sampaio; Jasvinder A Singh; Ilona Steigerwald; Vibeke Strand; Leslie A Tive; Jeffrey Tobias; Ajay D Wasan; Hilary D Wilson
Journal:  Pain       Date:  2021-09-09       Impact factor: 7.926

Review 4.  Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.

Authors:  Francesco Pignatti; Bertil Jonsson; Gideon Blumenthal; Robert Justice
Journal:  Mol Oncol       Date:  2014-10-16       Impact factor: 6.603

Review 5.  A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions.

Authors:  Henk Broekhuizen; Catharina G M Groothuis-Oudshoorn; Janine A van Til; J Marjan Hummel; Maarten J IJzerman
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

Review 6.  Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.

Authors:  Anneloes van Walsem; Shaloo Pandhi; Richard M Nixon; Patricia Guyot; Andreas Karabis; R Andrew Moore
Journal:  Arthritis Res Ther       Date:  2015-03-19       Impact factor: 5.156

Review 7.  Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring.

Authors:  Eoin O'Brien; J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-11       Impact factor: 3.738

8.  Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?

Authors:  Eric P Brass
Journal:  Diabetes Care       Date:  2013-05-21       Impact factor: 19.112

9.  Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Authors:  Bennett Levitan; Zhong Yuan; Alexander G G Turpie; Richard J Friedman; Martin Homering; Jesse A Berlin; Scott D Berkowitz; Rachel B Weinstein; Peter M DiBattiste
Journal:  Vasc Health Risk Manag       Date:  2014-03-26

10.  Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.

Authors:  Holland C Detke; John Lauriello; John Landry; David P McDonnell
Journal:  Int J Methods Psychiatr Res       Date:  2014-07-03       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.